Woodline Partners LP grew its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 498,732 shares of the company's stock after acquiring an additional 91,829 shares during the quarter. Woodline Partners LP owned about 1.67% of Silence Therapeutics worth $3,431,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Barclays PLC boosted its holdings in Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares in the last quarter. Marshall Wace LLP raised its stake in Silence Therapeutics by 190.3% during the 4th quarter. Marshall Wace LLP now owns 488,889 shares of the company's stock valued at $3,364,000 after acquiring an additional 320,472 shares during the last quarter. Nantahala Capital Management LLC lifted its position in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock worth $7,222,000 after acquiring an additional 849,676 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Silence Therapeutics in the 4th quarter valued at approximately $26,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Silence Therapeutics by 50.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company's stock valued at $887,000 after purchasing an additional 43,289 shares during the period. Institutional investors and hedge funds own 98.73% of the company's stock.
Silence Therapeutics Stock Performance
NASDAQ SLN traded up $0.68 during trading hours on Thursday, reaching $5.87. The company's stock had a trading volume of 164,852 shares, compared to its average volume of 300,664. The company's 50-day moving average is $3.52 and its two-hundred day moving average is $5.40. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $22.47. The stock has a market cap of $175.69 million, a PE ratio of -3.74 and a beta of 1.20.
Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. Equities analysts expect that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on SLN shares. Morgan Stanley lowered their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. BMO Capital Markets cut their price objective on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. Chardan Capital lowered their price target on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group dropped their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $33.83.
View Our Latest Analysis on Silence Therapeutics
Silence Therapeutics Company Profile
(
Free Report)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Featured Stories
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
